Simulations Plus debuts COVID-19 consulting program

By The Science Advisory Board staff writers

March 27, 2020 -- Medical simulation software company Simulations Plus announced that it has created a program to speed up consulting assistance to scientists working on COVID-19 research.

As part of its StrategiesPlus COVID-19 ACT program, each division of the company will provide specialized expertise to help develop safe, effective treatments. It offers the following:

  • Mechanistic GastroPlus pulmonary simulations to investigate alternative dosing modalities and optimize dosing to target lung exposure
  • Application of GastroPlus modeling and simulation data in regulatory reports to support repurposing strategies or drug product quality claims
  • Utilization of quantitative systems toxicology and pharmacology models from drug-induced liver injury modeling software to predict potential liver toxicity risk, efficacy potential for pulmonary injury-related pathophysiology, or efficacy potential for cardiac injury-related pathophysiology of drug candidate treatments for COVID-19
  • Semi-mechanistic drug and disease modeling and simulation support, including implementation of viral dynamics models for clinical and strategic decision-making and regulatory submissions
  • Comprehensive clinical pharmacology consulting for drug development and regulatory interaction

Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...
COVID-19 causes long-term disruptions to clinical trials
New survey results suggest that clinical trials are experiencing significant roadblocks associated with COVID-19. These could ultimately result in a slowdown...
Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership,...
Frontera supercomputer aids COVID-19 drug development
Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million...
TriNetX updates platform to support COVID-19 research
Global health research network TriNetX said that it has updated its real-world data platform to incorporate specific terminology for COVID-19 test results.
NIH shifts noncritical research to maintenance
The National Institutes of Health (NIH) has decided to shift all laboratory operations that are not mission critical to a maintenance phase, according...

Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter